EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Neoadjuvant Therapy in Differentiated Thyroid Cancer

Rajan P Dang iD, Daniel McFarland iD, Valerie H Le, Nadia Camille, Brett A Miles, Marita S Teng, Eric M Genden, Krzysztof J Misiukiewicz

International Journal of Surgical Oncology · 2016 · 2016 · 1-8

DOI: 10.1155/2016/3743420 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Surgical Oncology, 2016. Verfasst von Rajan P Dang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Education, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Invasion of differentiated thyroid cancer (DTC) into surrounding structures can lead to morbid procedures such as laryngectomy and tracheal resection. In these patients, there is a potential role for neoadjuvant therapy.

Methods

We identified three studies involving the treatment of DTC with neoadjuvant chemotherapy: two from Slovenia and one from Japan.

Results

These studies demonstrate that in selected situations, neoadjuvant chemotherapy can have a good response and allow for a more complete surgical resection, the treatment of DTC. Additionally, the SELECT trial shows that the targeted therapy lenvatinib is effective in the treatment of DTC and could be useful as neoadjuvant therapy for this disease due to its short time to response. Pazopanib has also demonstrated promise in phase II data.

Conclusions

Thus, chemotherapy in the neoadjuvant setting could possibly be useful for managing advanced DTC. Additionally, some of the new tyrosine kinase inhibitors (TKIs) hold promise for use in the neoadjuvant setting in DTC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenocarcinomaAntibiotics, AntineoplasticAntineoplastic AgentsClinical Trials as TopicDoxorubicinHumansIndazolesJapanMolecular Targeted TherapyNeoadjuvant TherapyNeoplasm StagingNiacinamidePhenylurea CompoundsProtein Kinase InhibitorsPyrimidinesQuinolinesSloveniaSorafenibSulfonamidesThyroid Neoplasms

Substanzen

Antibiotics, AntineoplasticAntineoplastic AgentsIndazolesPhenylurea CompoundsProtein Kinase InhibitorsPyrimidinesQuinolinesSulfonamidesNiacinamidepazopanib

Autor:innen und Institutionen

  • Department of Medical Education, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Department of Hematology-Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Department of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

ORCID-Profile: Rajan P Dang, Daniel McFarland

Zitieren

APA

Dang, R. P., McFarland, D., Le, V. H., Camille, N., Miles, B. A., Teng, M. S., Genden, E. M., & Misiukiewicz, K. J. (2016). Neoadjuvant Therapy in Differentiated Thyroid Cancer. International Journal of Surgical Oncology, 2016, 1-8. https://doi.org/10.1155/2016/3743420

Vancouver

Dang RP, McFarland D, Le VH, Camille N, Miles BA, Teng MS, et al. Neoadjuvant Therapy in Differentiated Thyroid Cancer. International Journal of Surgical Oncology. 2016;2016:1-8. doi:10.1155/2016/3743420

BibTeX
@article{Dang2016,
  author = {Dang, Rajan P and McFarland, Daniel and Le, Valerie H and Camille, Nadia and Miles, Brett A and Teng, Marita S and Genden, Eric M and Misiukiewicz, Krzysztof J},
  title = {Neoadjuvant Therapy in Differentiated Thyroid Cancer},
  journal = {International Journal of Surgical Oncology},
  year = {2016},
  volume = {2016},
  pages = {1--8},
  doi = {10.1155/2016/3743420}
}
Kostenlos starten →